These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829 [TBL] [Abstract][Full Text] [Related]
3. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318 [TBL] [Abstract][Full Text] [Related]
4. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324 [TBL] [Abstract][Full Text] [Related]
5. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520 [TBL] [Abstract][Full Text] [Related]
6. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421 [TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054 [TBL] [Abstract][Full Text] [Related]
8. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857 [TBL] [Abstract][Full Text] [Related]
10. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778 [TBL] [Abstract][Full Text] [Related]
11. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762 [TBL] [Abstract][Full Text] [Related]
12. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627 [TBL] [Abstract][Full Text] [Related]
13. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001 [TBL] [Abstract][Full Text] [Related]
14. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472 [TBL] [Abstract][Full Text] [Related]
15. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Crisafulli A; Micari A; Altavilla D; Saporito F; Sardella A; Passaniti M; Raffa S; D'anneo G; Lucà F; Mioni C; Arrigo F; Squadrito F Clin Sci (Lond); 2005 Oct; 109(4):389-95. PubMed ID: 15926884 [TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262 [TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158 [TBL] [Abstract][Full Text] [Related]
19. [Pathophysiological significance and clinical utility of circulating osteoprotegerin]. Dovio A; Data V; Angeli A Ann Ital Med Int; 2004; 19(1):8-19. PubMed ID: 15176704 [TBL] [Abstract][Full Text] [Related]
20. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? Dovio A; Data V; Angeli A J Endocrinol Invest; 2005; 28(10 Suppl):14-22. PubMed ID: 16550717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]